Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

January 01, 2013 (Vol. 33, No. 1)

Where Downstream Operations Are Headed

  • "By 2016, six out of ten of the blockbusters will be monoclonal-antibody-based therapeutics. With patent protection ending on many of these blockbusters by 2020 and this market estimated to be worth $100 billion a year, it is clear why developing biosimilars is attractive,” stated Stuart Melville, purification team leader ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.